Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent? | J Immunother Cancer | 2023 | 37541690 | PubTator, text mining | PubMed |
| Disulfidptosis-associated LncRNAs index predicts prognosis and chemotherapy drugs sensitivity in cervical cancer. | Sci Rep | 2023 | 37528124 | PubTator, text mining | PubMed |
| Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta. | Front Immunol | 2023 | 37520560 | PubTator, text mining | PubMed |
| Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates. | Pharmaceutics | 2023 | 37513979 | PubTator, text mining | PubMed |
| Bridging Pyroptosis and Immunity: A Comprehensive Study of the Pyroptosis-Related Long Non-Coding RNA Signature in Breast Cancer. | Life (Basel) | 2023 | 37511974 | PubTator, text mining | PubMed |
| From Teeth to Therapy: A Review of Therapeutic Potential within the Secretome of Stem Cells from Human Exfoliated Deciduous Teeth. | Int J Mol Sci | 2023 | 37511524 | PubTator, text mining | PubMed |
| Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy. | Cancers (Basel) | 2023 | 37509394 | PubTator, text mining | PubMed |
| Prediction of Prognosis, Immunotherapy and Chemotherapy with an Immune-Related Risk Score Model for Endometrial Cancer. | Cancers (Basel) | 2023 | 37509334 | PubTator, text mining | PubMed |
| The Emerging Role of Innate Lymphoid Cells (ILCs) and Alarmins in Celiac Disease: An Update on Pathophysiological Insights, Potential Use as Disease Biomarkers, and Therapeutic Implications. | Cells | 2023 | 37508573 | PubTator, text mining | PubMed |
| Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). | J Transl Med | 2023 | 37507765 | PubTator, text mining | PubMed |
| The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer. | Front Oral Health | 2023 | 37496754 | PubTator, text mining | PubMed |
| Leveraging translational insights toward precision medicine approaches for brain metastases. | Nat Cancer | 2023 | 37491527 | PubTator, text mining | PubMed |
| Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers. | Cell Death Dis | 2023 | 37488117 | PubTator, text mining | PubMed |
| Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma. | Cancer Res Commun | 2023 | 37484198 | PubTator, text mining | PubMed |
| A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors. | Front Immunol | 2023 | 37483633 | PubTator, text mining | PubMed |
| Insight of a lipid metabolism prognostic model to identify immune landscape and potential target for retroperitoneal liposarcoma. | Front Immunol | 2023 | 37483592 | PubTator, text mining | PubMed |
| Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma. | World J Surg Oncol | 2023 | 37481543 | PubTator, text mining | PubMed |
| Cuproptosis-related lncRNAs predict prognosis and immune response of thyroid carcinoma. | Front Genet | 2023 | 37470034 | PubTator, text mining | PubMed |
| Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD. | Cell Rep Med | 2023 | 37467715 | PubTator, text mining | PubMed |
| CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy. | J Immunol | 2023 | 37466381 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=23